--- title: "AstraZeneca Gets U.S. Approval for Hypertension Drug" type: "News" locale: "en" url: "https://longbridge.com/en/news/286724028.md" description: "AstraZeneca has received U.S. approval for its hypertension drug, Baxfendy (formerly baxdrostat), which targets aldosterone to lower blood pressure. The company anticipates peak annual sales exceeding $5 billion. This approval enhances AstraZeneca's portfolio in cardiovascular and renal treatments, following the patent expiration of its diabetes drug, Farxiga. The FDA's decision was based on successful late-stage trials showing efficacy in patients with uncontrolled hypertension. AstraZeneca aims to launch 20 new medicines by 2030, targeting $80 billion in revenue." datetime: "2026-05-18T06:30:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286724028.md) - [en](https://longbridge.com/en/news/286724028.md) - [zh-HK](https://longbridge.com/zh-HK/news/286724028.md) --- # AstraZeneca Gets U.S. Approval for Hypertension Drug By Adria Calatayud AstraZeneca said it received U.S. approval for a new hypertension treatment, getting the green light to launch a drug the U.K. pharmaceutical company expects to generate multibillion-dollar annual sales at its peak. The drug, known until now as baxdrostat, will be marketed under the brand name Baxfendy, the company said Monday. The approval expands AstraZeneca's cardiovascular, renal and metabolism portfolio shortly after diabetes drug Farxiga--its biggest product in that therapeutic area and the bestselling medicine in the company's history--went off patent in the U.S. AstraZeneca said that Baxfendy treats hypertension in a new way by targeting aldosterone, a hormone that raises blood pressure. Ruud Dobber, executive vice president of AstraZeneca's biopharmaceuticals business, said the approval brings a new treatment to a disease that has had little therapeutic progress for the past two decades. The U.S. Food and Drug Administration approved the drug as a treatment of hypertension in adults in combination with other medications, the company said. The decision was based on results of a late-stage clinical trial that showed the drug reduced blood pressure in patients with uncontrolled hypertension who were on two or more medications, it added. Executives at AstraZeneca previously said revenue from the product could top $5 billion at its peak. The drug is one of the 20 new medicines the company aims to launch by the end of the decade, as part of its goal to achieve revenue of $80 billion by 2030. AstraZeneca, which gained control of Baxfendy through its acquisition of CinCor Pharma in 2023, is looking to expand its portfolio in cardiovascular, renal and metabolism diseases with new products such as its experimental drug, elecoglipron, for weight loss. Write to Adria Calatayud at adria.calatayud@wsj.com (END) Dow Jones Newswires May 18, 2026 02:20 ET (06:20 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### Related Stocks - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) - [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md) - [CINC.US](https://longbridge.com/en/quote/CINC.US.md) ## Related News & Research - [AstraZeneca's blood pressure drug wins U.S. approval](https://longbridge.com/en/news/286720674.md) - [AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension](https://longbridge.com/en/news/286904730.md) - [](https://longbridge.com/en/news/286792193.md) - [AstraZeneca Tracks Real-World Sinus Surgery Outcomes in China: What Investors Should Watch](https://longbridge.com/en/news/286132902.md) - [AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios](https://longbridge.com/en/news/286801629.md)